Sintilimab

信迪利单抗

Report date: 2026/05/21 17:30:33

Base Information

Drug NameSintilimab
Drug Alias NameSindilizumab信迪单抗注射液SindillimabSinilimabSindilimab +[12] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed cell death protein 1 blockers
TargetsProgrammed cell death protein 1
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaOral Squamous Cell CarcinomaGastroesophageal Junction Neoplasms +[31] 
Global Approved IndicationsHodgkin Disease
Approved Indications in ChinaHodgkin Disease
Original Approved Country/TerritoryMainland China
Original Approved Date2018/12/24
Country/TerritoryBelgiumUnited StatesHungary +[7] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesCancer Hospital Of Chinese Academy Of Medical SciencesSun Yat-Sen Memorial Hospital Of Sun Yat-Sen UniversityInnovent Biologics Technology Ltd +[11] 
Inactive CompaniesInnovent Biologics IncChinese Academy Of Medical SciencesSichuan University +[5] 
Active IndicationsPrimary mediastinal B cell lymphomaOral Squamous Cell CarcinomaGastroesophageal Junction Neoplasms +[22] 
Inactive IndicationsSolid tumoursLung DiseasesRespiratory Tract Diseases +[9] 

Other Information

ATC CodeL01XC
Related LinksWikipediaDrugBankKEGG